Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity by Andrew Overholser, Eric Czech, Linda Speer, Joel Wilson, Alex Overholser

Subjects: Get full text

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review by Aleksander Jentkiewicz, Esmail Haj Obeid, Jakub Ulrych, Jan Krupa, Maciej Malinowski, Michał Krasowski, Alicja Kalinowska, Wiktoria Pietras, Adrian Kozieł, Zofia Kurek

Subjects: Get full text

Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report by Elisa Dinoi, Giuseppe Daniele, Giuseppe Daniele, Angela Michelucci, Fulvia Baldinotti, Fabrizio Campi, Piero Marchetti, Stefano Del Prato, Angela Dardano, Angela Dardano

Subjects: Get full text

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (H... by Darshan Hullon, Ghasaq K. Subeh, Yelizaveta Volkova, Karolina Janiec, Adam Trach, Ruslan Mnevets

Subjects: Get full text

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus by Alexander C. Martins, Beatriz G. de la Torre, Fernando Albericio

Subjects: Get full text